KR101614938B1 - 균막 치료 - Google Patents

균막 치료 Download PDF

Info

Publication number
KR101614938B1
KR101614938B1 KR1020107003308A KR20107003308A KR101614938B1 KR 101614938 B1 KR101614938 B1 KR 101614938B1 KR 1020107003308 A KR1020107003308 A KR 1020107003308A KR 20107003308 A KR20107003308 A KR 20107003308A KR 101614938 B1 KR101614938 B1 KR 101614938B1
Authority
KR
South Korea
Prior art keywords
protein
proteins
growth
bacterial
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107003308A
Other languages
English (en)
Korean (ko)
Other versions
KR20100051656A (ko
Inventor
스튜어트 제프리 대쉬퍼
에릭 찰스 레이놀즈
파울 데이비드 베쓰
칭 셍 앙
Original Assignee
오럴 헬스 오스트레일리아 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40228120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101614938(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2007903788A external-priority patent/AU2007903788A0/en
Application filed by 오럴 헬스 오스트레일리아 피티와이 엘티디 filed Critical 오럴 헬스 오스트레일리아 피티와이 엘티디
Publication of KR20100051656A publication Critical patent/KR20100051656A/ko
Application granted granted Critical
Publication of KR101614938B1 publication Critical patent/KR101614938B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020107003308A 2007-07-12 2008-07-11 균막 치료 Expired - Fee Related KR101614938B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007903788A AU2007903788A0 (en) 2007-07-12 Biofilm treatment
AU2007903788 2007-07-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020160006951A Division KR20160013240A (ko) 2007-07-12 2016-01-20 균막 치료

Publications (2)

Publication Number Publication Date
KR20100051656A KR20100051656A (ko) 2010-05-17
KR101614938B1 true KR101614938B1 (ko) 2016-04-22

Family

ID=40228120

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107003308A Expired - Fee Related KR101614938B1 (ko) 2007-07-12 2008-07-11 균막 치료
KR1020160006951A Ceased KR20160013240A (ko) 2007-07-12 2016-01-20 균막 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020160006951A Ceased KR20160013240A (ko) 2007-07-12 2016-01-20 균막 치료

Country Status (13)

Country Link
US (2) US8241611B2 (enExample)
EP (2) EP2175851B1 (enExample)
JP (1) JP5476297B2 (enExample)
KR (2) KR101614938B1 (enExample)
CN (2) CN103357014A (enExample)
AU (1) AU2008274906B2 (enExample)
CA (1) CA2693695C (enExample)
DK (1) DK2175851T3 (enExample)
ES (2) ES2714008T3 (enExample)
NZ (2) NZ595252A (enExample)
PL (1) PL2175851T3 (enExample)
SG (1) SG183016A1 (enExample)
WO (1) WO2009006699A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
US8129500B2 (en) * 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
US20100092471A1 (en) 2006-06-27 2010-04-15 Oral Health Australia Pty Ltd Porphyromonas Gingivalis Polypeptides Useful in the Prevention of Periodontal Disease
CN101842486A (zh) 2007-07-12 2010-09-22 口腔健康澳洲私人有限公司 生物膜的免疫治疗
ES2714008T3 (es) 2007-07-12 2019-05-24 Oral Health Australia Pty Ltd Tratamiento de biopelícula
CN107266582B (zh) 2008-08-29 2021-09-10 口腔健康澳洲私人有限公司 牙龈卟啉单胞菌感染的预防、治疗和诊断
TWI391148B (zh) * 2009-04-01 2013-04-01 美國棕欖公司 含有生物可接受性及生物活性之玻璃的非水性牙膏組成物及其使用與製造之方法
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
KR101352795B1 (ko) * 2010-02-26 2014-02-17 주식회사 나이벡 치아의 접합능을 향상시키기 위한 치과용 클린저 조성물
MY162557A (en) 2010-02-26 2017-06-15 Oral Health Australia Pty Ltd Treatment or prevention of infection
US20120052052A1 (en) * 2010-08-27 2012-03-01 The Regents Of The University Of Michigan Control of biofilm formation
US9549904B2 (en) 2012-06-06 2017-01-24 Thomas Bryan Method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin
US9480669B2 (en) 2015-01-06 2016-11-01 The Regents Of The University Of California Method of destroying and preventing bacterial and fungal biofilm by amino acid infusion
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US9795809B2 (en) 2013-12-23 2017-10-24 Embro Corporation Use of moss to improve dental health
US20180207067A1 (en) 2015-07-14 2018-07-26 Research Institute at Nationwide Children's Hospit al Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en) * 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
AU2018206560B9 (en) 2017-01-04 2025-04-03 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
JP7514621B2 (ja) 2017-01-04 2024-07-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
WO2018226987A1 (en) 2017-06-07 2018-12-13 The Regents Of The University Of California Compositions for treating fungal and bacterial biofilms and methods of using the same
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
KR20210070331A (ko) 2018-10-05 2021-06-14 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 생물막 제거를 위한 hmgb1 단백질 유도체
WO2020117755A1 (en) 2018-12-03 2020-06-11 The Regents Of The University Of California Compositions and methods for treating biofilms
US12109176B1 (en) 2023-04-20 2024-10-08 Thomas Bryan Effect of glycerol on biofilm forming bacteria and fungi that changes the microbes sensitivity to pro and anti-biofilm non-toxic, non-bonded plasma amino acids and amino acid derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2381449A (en) * 2001-10-31 2003-05-07 Smithkline Beecham Plc Oral hygiene compositions comprising an electron acceptor

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US5210035A (en) * 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5830710A (en) 1988-09-08 1998-11-03 University Of Florida Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease
WO1994027606A1 (en) * 1993-05-28 1994-12-08 Unisearch Limited Method of treating helicobacter pylori infection
US5711937A (en) * 1993-06-28 1998-01-27 Lion Corporation Oral composition
US5475097A (en) * 1993-10-21 1995-12-12 University Of Georgia Research Foundation, Inc. Lysine-specific Porphyromonas gingivalis proteinase
US5523390A (en) * 1993-09-10 1996-06-04 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
US6017532A (en) * 1993-09-10 2000-01-25 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
WO1995007286A1 (en) 1993-09-10 1995-03-16 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase coding sequences
JPH0797395A (ja) 1993-09-28 1995-04-11 Kyowa Medex Co Ltd ポルフイロモナス・ジンジバリス線毛蛋白質の配列を含有するペプチド類及びその用途
US5948636A (en) 1994-03-29 1999-09-07 Kyowa Hakko Kogyo Co., Ltd. DNA and host cells encoding a cell surface protein of porphyromonas gingivalis
AUPN627595A0 (en) * 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
JP2000507245A (ja) * 1996-03-22 2000-06-13 ユニバーシティー オブ ジョージア リサーチ ファウンデーション，インコーポレイテッド Ｐｏｒｐｈｙｒｏｍｏｎａｓ ｇｉｎｇｉｖａｌｉｓペプチドを含む免疫原性組成物および方法
AUPN901296A0 (en) * 1996-03-29 1996-04-26 University Of Melbourne, The Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPO652897A0 (en) * 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
US8129500B2 (en) * 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
ATE534742T1 (de) 1997-12-10 2011-12-15 Csl Ltd Polypeptide und nukleinsäuren von phorphorymonas gingivalis
AUPP083997A0 (en) * 1997-12-10 1998-01-08 Csl Limited Porphyromonas gingivalis nucleotides
US6444799B1 (en) * 1997-12-31 2002-09-03 Csl Limited P. gingivalis polynucleotides and uses thereof
AUPP893999A0 (en) * 1999-03-01 1999-03-25 Csl Limited Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis
EP1210182A1 (en) * 1999-05-12 2002-06-05 The General Hospital Corporation Permeabilizing biofilms
GB9913437D0 (en) 1999-06-09 1999-08-11 Medical Res Council Fusion proteins
AUPQ485999A0 (en) * 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
AUPQ718200A0 (en) * 2000-04-28 2000-05-25 Csl Limited Porphyromonas gingivalis recombinant proteins and truncations
US6576226B1 (en) * 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6726898B2 (en) * 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US20030083287A1 (en) * 2000-11-30 2003-05-01 Burgess Nicola A. ginS
AUPR575401A0 (en) 2001-06-18 2001-07-12 Unisearch Limited Method of causing sloughing
JP2003192616A (ja) 2001-12-27 2003-07-09 Univ Nihon 歯周病用ｄｎａワクチン
JP2003286191A (ja) 2002-03-27 2003-10-07 Univ Nihon 歯周病用粘膜免疫ワクチン
JPWO2004083425A1 (ja) * 2003-03-17 2006-06-22 麒麟麦酒株式会社 歯周病治療剤
AU2004266213A1 (en) * 2003-08-15 2005-03-03 University Of Florida Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases
WO2005076010A2 (en) * 2004-02-06 2005-08-18 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
US20070098649A1 (en) * 2004-03-22 2007-05-03 The Board Of Trustees Of The University Of Illinois Method and composition for controlling oral pathogens
EP1799705A4 (en) * 2004-09-23 2008-11-05 Univ Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
WO2008016385A2 (en) 2006-01-20 2008-02-07 The University Of Washington Deacylase polypeptides, deacylase polynucleotides, and methods of use thereof
US20100092471A1 (en) * 2006-06-27 2010-04-15 Oral Health Australia Pty Ltd Porphyromonas Gingivalis Polypeptides Useful in the Prevention of Periodontal Disease
WO2008124646A2 (en) 2007-04-06 2008-10-16 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Use of amyloid proteins as vaccine scaffolds
ES2714008T3 (es) 2007-07-12 2019-05-24 Oral Health Australia Pty Ltd Tratamiento de biopelícula
CN101842486A (zh) * 2007-07-12 2010-09-22 口腔健康澳洲私人有限公司 生物膜的免疫治疗
CN107266582B (zh) 2008-08-29 2021-09-10 口腔健康澳洲私人有限公司 牙龈卟啉单胞菌感染的预防、治疗和诊断
US20110104179A1 (en) * 2009-06-19 2011-05-05 Oral Health Australia Pty Ltd Protease inhibitory peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2381449A (en) * 2001-10-31 2003-05-07 Smithkline Beecham Plc Oral hygiene compositions comprising an electron acceptor

Also Published As

Publication number Publication date
CN101842097B (zh) 2013-06-19
US8895019B2 (en) 2014-11-25
ES2432690T3 (es) 2013-12-04
CA2693695A1 (en) 2009-01-15
SG183016A1 (en) 2012-08-30
DK2175851T3 (da) 2013-07-15
US8241611B2 (en) 2012-08-14
AU2008274906B2 (en) 2013-11-07
NZ582474A (en) 2012-03-30
EP2638905A3 (en) 2014-03-05
NZ595252A (en) 2013-11-29
HK1143530A1 (en) 2011-01-07
US20130028847A1 (en) 2013-01-31
ES2714008T3 (es) 2019-05-24
EP2175851B1 (en) 2013-05-15
PL2175851T3 (pl) 2013-11-29
EP2638905B1 (en) 2019-01-16
US20100209362A1 (en) 2010-08-19
CA2693695C (en) 2016-06-07
KR20100051656A (ko) 2010-05-17
WO2009006699A1 (en) 2009-01-15
EP2175851A1 (en) 2010-04-21
EP2638905A2 (en) 2013-09-18
JP5476297B2 (ja) 2014-04-23
KR20160013240A (ko) 2016-02-03
CN101842097A (zh) 2010-09-22
EP2175851A4 (en) 2011-03-16
AU2008274906A1 (en) 2009-01-15
JP2010532765A (ja) 2010-10-14
CN103357014A (zh) 2013-10-23

Similar Documents

Publication Publication Date Title
KR101614938B1 (ko) 균막 치료
US8911745B2 (en) Immunology treatment for biofilms
US7087228B2 (en) Preventing tooth decay and infective endocarditis using natural oligopeptides
EP2969003A1 (en) Methods and compositions for bacteria infections
JP2015504417A (ja) ジンジパイン阻害プロペプチド
HK1189800A (en) Biofilm treatment
HK1189800B (en) Biofilm treatment
HK1143530B (en) Biofilm treatment
AU2013203251A1 (en) Biofilm treatment
AU2013203250A1 (en) Immunology treatment for biofilms
HK1185102A (en) Immunology treatment for biofilms
WO2026006209A1 (en) Compositions including n-acetyl-d-glucosamine (glcnac) as a prebiotic agent against multiple oral diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190328

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210419

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210419